Digital health company, NeuroRPM, has received FDA clearance for its artificial intelligence (AI)-powered remote monitoring app for Parkinson’s disease.
The product uses AI and Apple Watch to continuously and passively monitor bradykinesia, tremor, and dyskinesia, the cardinal symptoms of Parkinson’s disease.
The product includes advanced, comprehensive monitoring capabilities for Parkinson’s disease available on a wearable device, allowing for day-to-day tracking of the full range of disease symptoms.
NeuroRPM consists of proprietary algorithms integrated into an Apple Watch app, that collects data passively through the user’s everyday use of the app.
The app is a convenient and effective way to continuously monitor symptoms and health metrics of Parkinson’s disease.
NeuroRPM is available by prescription, and only uses data from Apple Watch that users have chosen to share with the app
Co-founder Dr Alexander Ksendzovsky, also the director of Functional Neurosurgery at the University of Maryland, said: “The clearance of NeuroRPM is a major milestone in the fight against Parkinson’s disease.
“This technology will allow for unprecedented insights into the symptoms of Parkinson’s disease including bradykinesia, tremor, and dyskinesia, using critical health and wellness data from Apple Watch. NeuroRPM is able to assess even slight changes with accuracy comparable to that of a neurologist. This changes the game for the treatment of Parkinson’s patients.
NeuroRPM President, Atila Omer, added: “We are thrilled to be on the new frontier of digital health with NeuroRPM. By leveraging the power of Apple Watch, we are transforming the way individuals with Parkinson’s disease understand their health, enabling care providers to make more informed clinical decisions which will lead to better health outcomes. We are honored to help drive this revolution in healthcare.”
NeuroRPM is the culmination of years of intellectual property development, clinical trials and technical research and represents a major advancement in the management of Parkinson’s disease.
Visit www.NeuroRPM.com for more information
